Table 2 Characteristics of the clinical metabotypes
|  | Favorable clinical metabotype (n = 99)* | Unfavorable clinical metabotype (n = 104)** |
|---|---|---|
n (%) | ||
 Men | 31 (31.3) | 39 (37.5) |
 Statin users | 5 (5.1) | 24 (23.1) |
 Anti-inflammatory drug users | 3 (3) | 4 (3.8) |
 Premenopausal women | 48 (71) | 18 (28) |
 Women using hormonal contraceptives | 27 (40) | 5 (8) |
Mean (SD) | ||
 Age (years) | 44 (12) | 55 (10) |
 BMI (kg/m2) | 30.9 (5.1) | 33.3 (4.7) |
 Waist circumference (cm) | 101.2 (14.0) | 111.9 (12.0) |
 HbA1c (mmol/mol) | 27 (14) | 33 (16) |
 Total-C (mmol/L) | 5.0 (0.9) | 5.1 (1.0) |
 LDL-C (mmol/L) | 3.3 (0.8) | 3.5 (1.0) |
Median (IQR) | ||
 HDL-C (mmol/L) | 1.4 (0.5) | 1.3 (0.4) |
 Triglycerides (mmol/L) | 1.15 (0.56) | 1.46 (1.02) |
 Lp(a) (mg/L) | 316 (498) | 202 (425) |
 Fasting glucose (mmol/L) | 4.9 (0.4) | 5.8 (0.8) |
 Insulin (pmol/L) | 61 (42) | 100 (77) |
 2-h glucose (mmol/L) | 4.7 (1.4) | 6.6 (2.6) |
 Systolic BP (mmHg) | 116 (14) | 124 (21) |
 Diastolic BP (mmHg) | 68 (12) | 72 (13) |
 CRP (mg/L) | 2.1 (3.1) | 3.8 (5.1) |